View
40
Download
5
Category
Preview:
DESCRIPTION
www.italiansarcomagroup.org. I. I. talian. talian. Started June 1997. S. S. arcoma. arcoma. G. G. roup. roup. Formalized October 2002. 6. 8. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 2. 1. 1. 2. 1. 1. 1. 1. 1. 2. 1. 1. 1. 1. 1. 1. 1. 5. 3. 3. 2. 1. - PowerPoint PPT Presentation
Citation preview
Italian
Sarcoma
Group
IItaliantalian
SSarcomaarcoma
GGrouproup
StartedJune 1997
StartedJune 1997
FormalizedOctober 2002Formalized
October 2002
www.italiansarcomagroup.org
68 Centers
• 14 National Institutes
• 14 Universities
• 34 Pubblic Hospitals
• 6 Private Hospitals
68 Centers
• 14 National Institutes
• 14 Universities
• 34 Pubblic Hospitals
• 6 Private Hospitals
Italian Sarcoma GroupItalian Sarcoma Group
210 members210 members
11
1 31
11
18
10 2
1
1 111
1 3
1
1
2 at november 2005at november 2005
11
1 1
1
2
5
1
1BELGIUM
1
1
2
11
11
1
6
1
• ISG/SSG I (localized disease): 3/1997 - 3/2001, 182 pts JCO 2005
• ISG/SSG II (metastatic disease): 3/1998 - 12/2002, 57 pts ASCO 2005
• ISG/OS I (localized disease) activated 4/2001, 212 pts
• EUROBOSS (ISG/SSG/COSS) (> 40 yrs) activated 12/2002, 79 pts
• High risk (relapsed patients) activated 12/2002, 28 pts
• ISG/SSG I (localized disease): 3/1997 - 3/2001, 182 pts JCO 2005
• ISG/SSG II (metastatic disease): 3/1998 - 12/2002, 57 pts ASCO 2005
• ISG/OS I (localized disease) activated 4/2001, 212 pts
• EUROBOSS (ISG/SSG/COSS) (> 40 yrs) activated 12/2002, 79 pts
• High risk (relapsed patients) activated 12/2002, 28 pts
Osteosarcoma ProtocolsOsteosarcoma ProtocolsItalian Sarcoma GroupItalian Sarcoma Group
• ISG/SSG III (standard risk)activated 6/99, 240 pts
• ISG/SSG IV (high risk)activated 6/99, 74 pts ASCO 2005
• ISG/AIEOP (very high risk)activated 12/2002, 19 pts
• Relapsed Patientsactivated 12/2002, 22 pts
• ISG/SSG III (standard risk)activated 6/99, 240 pts
• ISG/SSG IV (high risk)activated 6/99, 74 pts ASCO 2005
• ISG/AIEOP (very high risk)activated 12/2002, 19 pts
• Relapsed Patientsactivated 12/2002, 22 pts
Ewing’s Sarcoma ProtocolsEwing’s Sarcoma ProtocolsItalian Sarcoma GroupItalian Sarcoma Group
• ISG/STS0101 (neoadjuvant EpiDOX+IFX, in high risk
localized disease) with Spanish Group (222 pts)
• ISG/STS 03/02 (neodjuvant IFO+RT in
retroperitoneal) (15 pts)
• HD-IFX in continuous infusion (2nd-4th line)
• Gemcytabine in leiomyosarcomas (2nd-3rd line)
• Paclitaxel in angiosarcomas (2a line)
• Miniallogenic Transplant (advanced disease,
responsive patients)
• Imatinib in advanced chordoma (35 pts)
• ISG/STS0101 (neoadjuvant EpiDOX+IFX, in high risk
localized disease) with Spanish Group (222 pts)
• ISG/STS 03/02 (neodjuvant IFO+RT in
retroperitoneal) (15 pts)
• HD-IFX in continuous infusion (2nd-4th line)
• Gemcytabine in leiomyosarcomas (2nd-3rd line)
• Paclitaxel in angiosarcomas (2a line)
• Miniallogenic Transplant (advanced disease,
responsive patients)
• Imatinib in advanced chordoma (35 pts)
Adult soft tissue sarcomas - ProtocolsAdult soft tissue sarcomas - ProtocolsItalian Sarcoma GroupItalian Sarcoma Group
• GIOTTO (observational, 2004-2005, in collaboration with
Novartis) (>700 pts)
• REGISTER (retrospective, histhological)
• 62024 (adjuvant Imatinib), intergroup with EORTC
• Institutions from the ISG participated in the following
studies on new agents in GIST:• SU11248 (international) CLOSED
• PTK787 (international)
• AMG706 (international)
• GIOTTO (observational, 2004-2005, in collaboration with
Novartis) (>700 pts)
• REGISTER (retrospective, histhological)
• 62024 (adjuvant Imatinib), intergroup with EORTC
• Institutions from the ISG participated in the following
studies on new agents in GIST:• SU11248 (international) CLOSED
• PTK787 (international)
• AMG706 (international)
GIST ProtocolsGIST Protocols
Possible accrualPossible accrual
Italian Population : 57 MillionsItalian Population : 57 Millions
Osteosarcoma: 90/120 (75%!)
Ewing’s Sarcoma: 50/60 (80%!)
Adult soft tissue sarcomas: 700/1400 (50%?)
Osteosarcoma: 90/120 (75%!)
Ewing’s Sarcoma: 50/60 (80%!)
Adult soft tissue sarcomas: 700/1400 (50%?)
Italian Sarcoma GroupItalian Sarcoma Group
Started January 1st, 2005 - 3 year projectStarted January 1st, 2005 - 3 year project
Total grant: 2.530.500,00 EuroTotal grant: 2.530.500,00 Euro
Website: WWW.PROTHETS.ORG
Dr. Piero Picci (Co-ordinator)
*Partner 1 Istituti Ortopedici Rizzoli (IOR, Italy)
Dr.ssa Katia Scotlandi
*Partner 2 Institut National de la Santé et de la Recherche Médicale (INSERM, France)
Pr. Alain Bernard
*Partner 3 Laboratory for Experimental Orthopaedic Research (UKM, Germany)
Dr. Frans van Valen
*Partner 4 University of Helsinki (UH.DMG, Finland)
Prof. Sakari Knuutila
*Partner 5 Department of Pathology, University of Valencia (UVEG, Spain)Prof. Antonio Lombart-Bosch
*Partner 6 Children´s Cancer Research Institute (CCRI, Austria)
Prof. Dr. Heinrich Kovar
*Partner 7 Université Paris 7 Denis-Diderot (UP7 DD, France)
Dr. Bernard Perbal
*Partner 8 Centre National de la Recherche Scientifique (CNRS, France)
Dr. Claude Malvy
*Partner 9 Belozersky Inst. of Physico-Chemical Biology of the Moscow State Univ. (BI.MSU)
Dr.ssa Marina Gottikh
*Partner 10 GenX Laboratories srl (GENX, Italy)
Dr. Alessandro Borsatti
*Partner 11 MABGENE S.A. (MABG, France)Agnès Leconte
Dr. Piero Picci (Co-ordinator)
*Partner 1 Istituti Ortopedici Rizzoli (IOR, Italy)
Dr.ssa Katia Scotlandi
*Partner 2 Institut National de la Santé et de la Recherche Médicale (INSERM, France)
Pr. Alain Bernard
*Partner 3 Laboratory for Experimental Orthopaedic Research (UKM, Germany)
Dr. Frans van Valen
*Partner 4 University of Helsinki (UH.DMG, Finland)
Prof. Sakari Knuutila
*Partner 5 Department of Pathology, University of Valencia (UVEG, Spain)Prof. Antonio Lombart-Bosch
*Partner 6 Children´s Cancer Research Institute (CCRI, Austria)
Prof. Dr. Heinrich Kovar
*Partner 7 Université Paris 7 Denis-Diderot (UP7 DD, France)
Dr. Bernard Perbal
*Partner 8 Centre National de la Recherche Scientifique (CNRS, France)
Dr. Claude Malvy
*Partner 9 Belozersky Inst. of Physico-Chemical Biology of the Moscow State Univ. (BI.MSU)
Dr.ssa Marina Gottikh
*Partner 10 GenX Laboratories srl (GENX, Italy)
Dr. Alessandro Borsatti
*Partner 11 MABGENE S.A. (MABG, France)Agnès Leconte
PROTHETS - OBJECTIVESPROTHETS - OBJECTIVES1. Prognostic factors: fusion transcripts, secondary
cytogenetic and molecular alterations, CD99, IGF-IR, NOVH, erbB-2, TTF1
2. Targeted therapeutic approaches: EWS/FLI1, CD99, erbB-2, IGF-IR, TRAIL
3. Genomic profiles for evaluation of tumor progression and response to chemotherapy
1. Prognostic factors: fusion transcripts, secondary cytogenetic and molecular alterations, CD99, IGF-IR, NOVH, erbB-2, TTF1
2. Targeted therapeutic approaches: EWS/FLI1, CD99, erbB-2, IGF-IR, TRAIL
3. Genomic profiles for evaluation of tumor progression and response to chemotherapy
WP3: Prognostic relevance of selected promising predictive markers
87 primary or established cell lines445 paraffin block material145 frozen material80 serum collected from ESFT pts3 tissue arraysMore than 200 inclusions for EM
87 primary or established cell lines445 paraffin block material145 frozen material80 serum collected from ESFT pts3 tissue arraysMore than 200 inclusions for EM
Evaluation of prognostic value of new genes
GALS3BP
HINT1
STOML2
CANX
FVT1
RPS4Y1
Prognostic value in a very small clinical series:
36 primary untreated biopsies, homogenous for histology, checked for RNA quality
Confirmatory studies: Protein analysis Tissue Array
Functional studies: in vitro siRNA silencing or forced expression
Recommended